Dinesh V Ph D Patel Protagonist Therapeutics, Inc (PTGX) insider trading activity

Dinesh V Ph D Patel is President and CEO of Protagonist Therapeutics, Inc. Currently has a direct ownership of 614,943 shares of PTGX, which is worth approximately $52 Million. The most recent transaction as insider was on Feb 15, 2024, when has been sold 3,717 shares (Common Stock) at a price of $28.23 per share, resulting in proceeds of $104,930. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 615K

18.26% 3M change

10.15% 12M change

Total Value Held $52 Million

DINESH V PH D PATEL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 15 2024	SELL Payment of exercise price or tax liability	$104,930 $28.23 p/Share	3,717 Reduced 0.6%	615,505 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	84,875 Added 12.05%	619,222 Common Stock
Dec 13 2023	SELL Open market or private sale	$1,505,999 $20.08 p/Share	75,000 Reduced 12.31%	534,347 Common Stock
Oct 18 2023	BUY Exercise of conversion of derivative security	$25,260 $4.21 p/Share	6,000 Added 0.98%	609,347 Common Stock
May 31 2023	SELL Payment of exercise price or tax liability	$317,141 $26.07 p/Share	12,165 Reduced 1.98%	602,946 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	30,000 Added 4.65%	615,111 Common Stock
Feb 22 2023	SELL Bona fide gift	-	10,000 Reduced 1.69%	583,448 Common Stock

Dec 28 2022	SELL Bona fide gift	-	3,116 Reduced 0.52%	598,096 Common Stock
Aug 23 2022	BUY Exercise of conversion of derivative security	$84,200 $4.21 p/Share	20,000 Added 3.2%	604,048 Common Stock
May 04 2022	SELL Bona fide gift	-	3,000 Reduced 0.51%	581,048 Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$66,274 $4.21 p/Share	15,742 Added 2.62%	584,048 Common Stock
Apr 26 2022	BUY Exercise of conversion of derivative security	$126,300 $4.21 p/Share	30,000 Added 5.01%	568,306 Common Stock
Apr 14 2022	BUY Exercise of conversion of derivative security	$64,424 $1.89 p/Share	34,087 Added 5.96%	537,847 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$112,853 $24.28 p/Share	4,648 Reduced 0.91%	503,760 Common Stock
Feb 15 2022	BUY Grant, award, or other acquisition	-	31,250 Added 5.79%	508,408 Common Stock
Dec 21 2021	SELL Open market or private sale	$482,100 $32.14 p/Share	15,000 Reduced 3.05%	477,158 Common Stock
Sep 21 2021	BUY Exercise of conversion of derivative security	$168,400 $4.21 p/Share	40,000 Added 7.52%	492,158 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	25,000 Added 5.25%	451,144 Common Stock
Jan 19 2021	SELL Open market or private sale	$611,212 $24.6 p/Share	24,846 Reduced 5.51%	426,144 Common Stock
Jan 19 2021	BUY Exercise of conversion of derivative security	$54,730 $4.21 p/Share	13,000 Added 2.8%	450,990 Common Stock

DVP

Dinesh V Ph D Patel

President and CEO

Newark, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Value

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX

Account